Current Data and Strategy in Glioblastoma Multiforme

Overview

Journal J Med Life

Specialty General Medicine

Date 2010 Jan 30

PMID 20108752

Citations 95

Authors

Gabriel Iacob

Eduard B Dinca

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) or astrocytoma grade IV on WHO classification is the most aggressive and the most frequent of all primary brain tumors. Glioblastoma is multiforme, resistant to therapeutic interventions illustrating the heterogeneity exhibited by this tumor in its every aspect, including clinical presentation, pathology, genetic signature. Current data and treatment strategy in GBM are presented focusing on basic science data and key clinical aspects like surgery, including personal experience; adjuvant modalities: radiotherapy, chemotherapy, but also for experimental approaches. Therapeutic attitude in recurrent GBM is also widely discussed.

Citing Articles

Role of Podoplanin (PDPN) in Advancing the Progression and Metastasis of Glioblastoma Multiforme (GBM).

Sharma B, Agriantonis G, Shafaee Z, Twelker K, Bhatia N, Kuschner Z Cancers (Basel). 2024; 16(23).

PMID: 39682237 PMC: 11639870. DOI: 10.3390/cancers16234051.

A new nano approach to prevent tumor growth in the local treatment of glioblastoma: Temozolomide and rutin-loaded hybrid layered composite nanofiber.

Ercelik M, Tekin C, Gurbuz M, Tuncbilekli Y, Dogan H, Mutlu B Asian J Pharm Sci. 2024; 19(6):100971.

PMID: 39640055 PMC: 11617954. DOI: 10.1016/j.ajps.2024.100971.

The role of NLRP3 and NLRP12 inflammasomes in glioblastoma.

Rajkhowa S, Jha S Genes Immun. 2024; 25(6):541-551.

PMID: 39604503 DOI: 10.1038/s41435-024-00309-z.

Glioblastoma invasion patterns from a clinical perspective-a systematic review.

Percuoco V, Herlin E, Prada F, Riva M, Pessina F, Staartjes V Neurosurg Rev. 2024; 47(1):864.

PMID: 39570467 PMC: 11582338. DOI: 10.1007/s10143-024-02944-6.

Emerging Gene-editing nano-therapeutics for Cancer.

Nujoom N, Koyakutty M, Biswas L, Rajkumar T, Nair S Heliyon. 2024; 10(21):e39323.

PMID: 39524822 PMC: 11550658. DOI: 10.1016/j.heliyon.2024.e39323.

References

Chung R, Whaley J, Kley N, Anderson K, Louis D, Menon A . TP53 gene mutations and 17p deletions in human astrocytomas. Genes Chromosomes Cancer. 1991; 3(5):323-31. DOI: 10.1002/gcc.2870030502. View

Hegi M, Diserens A, Gorlia T, Hamou M, De Tribolet N, Weller M . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10):997-1003. DOI: 10.1056/NEJMoa043331. View

Batzdorf U, MALAMUD N . THE PROBLEM OF MULTICENTRIC GLIOMAS. J Neurosurg. 1963; 20:122-36. DOI: 10.3171/jns.1963.20.2.0122. View

Ostermann S, Csajka C, Buclin T, Leyvraz S, Lejeune F, Decosterd L . Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clin Cancer Res. 2004; 10(11):3728-36. DOI: 10.1158/1078-0432.CCR-03-0807. View

Lacroix M, Abi-Said D, Fourney D, Gokaslan Z, Shi W, Demonte F . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2002; 95(2):190-8. DOI: 10.3171/jns.2001.95.2.0190. View

Westphal M, Hilt D, Bortey E, Delavault P, Olivares R, Warnke P . A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003; 5(2):79-88. PMC: 1920672. DOI: 10.1093/neuonc/5.2.79. View

Holland E, Hively W, DePinho R, Varmus H . A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev. 1998; 12(23):3675-85. PMC: 317252. DOI: 10.1101/gad.12.23.3675. View

ROBERTS W, Palade G . Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995; 108 ( Pt 6):2369-79. DOI: 10.1242/jcs.108.6.2369. View

Inskip P, Tarone R, Hatch E, Wilcosky T, Shapiro W, Selker R . Cellular-telephone use and brain tumors. N Engl J Med. 2001; 344(2):79-86. DOI: 10.1056/NEJM200101113440201. View

10.

Lonardi S, Tosoni A, Brandes A . Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev. 2005; 31(2):79-89. DOI: 10.1016/j.ctrv.2004.12.005. View

11.

Sotelo J, Briceno E, Lopez-Gonzalez M . Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006; 144(5):337-43. DOI: 10.7326/0003-4819-144-5-200603070-00008. View

12.

Simmons M, Lamborn K, Takahashi M, Chen P, Israel M, Berger M . Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001; 61(3):1122-8. View

13.

Kitange G, Templeton K, Jenkins R . Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol. 2003; 15(3):197-203. DOI: 10.1097/00001622-200305000-00003. View

14.

Levin V, Silver P, Hannigan J, Wara W, Gutin P, Davis R . Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990; 18(2):321-4. DOI: 10.1016/0360-3016(90)90096-3. View

15.

Day 3rd R, Ziolkowski C, Scudiero D, Meyer S, Lubiniecki A, Girardi A . Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature. 1980; 288(5792):724-7. DOI: 10.1038/288724a0. View

16.

Yarosh D, Scudiero D, Yagi T, Day 3rd R . Human tumor cell strains both unable to repair O6-methylguanine and hypersensitive to killing by human alpha and beta interferons. Carcinogenesis. 1985; 6(6):883-6. DOI: 10.1093/carcin/6.6.883. View

17.

Gerson S . MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer. 2004; 4(4):296-307. DOI: 10.1038/nrc1319. View

18.

Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K . Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342(6250):705-8. DOI: 10.1038/342705a0. View

19.

Zuo C, Ai L, Ratliff P, Suen J, Hanna E, Brent T . O6-methylguanine-DNA methyltransferase gene: epigenetic silencing and prognostic value in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2004; 13(6):967-75. View

20.

Rajasekhar V, Viale A, Socci N, Wiedmann M, Hu X, Holland E . Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell. 2003; 12(4):889-901. DOI: 10.1016/s1097-2765(03)00395-2. View